1,870€
-1,58%
Echtzeit-Aktienkurs PURETECH HEALTH PLC LS 1
Bid:
Ask:
Echtzeit-Chart der PURETECH HEALTH PLC LS 1 Aktie
Börsenkurse PURETECH HEALTH PLC LS 1
| Pfund Indikation | - | - | - | - | £1,569 | -1,60% |
| Nasdaq | - | - | - | - | - | - |
| Börse Stuttgart | - | - | - | - | 1,870€ | -1,58% |
| Börse Frankfurt | - | - | - | - | 1,880€ | -2,59% |
| Echtzeit Euro | - | - | - | - | 1,880€ | -3,34% |
Fundamentaldaten der PURETECH HEALTH PLC LS 1 Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [GBP] | 2,68 Mio. | -24,17 Mio. | -52,85 Mio. | -0,19 | - | - | 189,77 |
| 2022 [GBP] | 12,68 Mio. | -52,80 Mio. | -40,88 Mio. | -0,14 | - | - | 41,08 |
| 2021 [GBP] | 12,64 Mio. | 10,72 Mio. | -44,03 Mio. | -0,15 | - | - | 42,57 |
| 2020 [GBP] | 9,18 Mio. | 41,40 Mio. | 4,67 Mio. | 0,02 | - | 116,88 | 58,26 |
| 2019 [GBP] | 7,69 Mio. | 350,92 Mio. | 330,12 Mio. | 1,17 | - | 1,61 | 69,42 |
| 2018 [GBP] | 15,56 Mio. | -42,71 Mio. | -32,74 Mio. | -0,12 | - | - | 33,95 |
| 2017 [GBP] | 1,97 Mio. | -41,23 Mio. | 23,97 Mio. | 0,10 | - | 18,51 | 226,06 |
| 2016 [GBP] | 3,28 Mio. | -61,65 Mio. | -36,16 Mio. | -0,16 | - | - | 135,18 |
| 2015 [GBP] | 7,74 Mio. | -36,86 Mio. | -25,78 Mio. | -0,14 | - | - | 54,63 |
| 2014 [GBP] | 1,35 Mio. | -46,29 Mio. | -25,29 Mio. | -0,31 | - | - | 314,90 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der PURETECH HEALTH PLC LS 1 Aktie
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect